Nā huahana

ʻO ka momona, ka maʻi maʻi type 2 a me ka hyperlipidemia e noho pū ana a pili pū me ka nui o ka maʻi maʻi a me ka make.Ua hoʻonui nui ʻia ka hoʻohana ʻana i ka waipaʻa i hoʻomaʻemaʻe ʻia a me ka fructose i nā makahiki i hala iho nei a ua hoʻohālikelike i ka piʻi ʻana o ka nui o ka momona a me ka maʻi diabetes.Ua hōʻike ʻia nā haʻawina kanaka a me nā holoholona e pili ana ka nui o ka fructose meaʻai me ka piʻi ʻana o ka dyslipidemia, ke kū ʻana o ka insulin, a me ke kiʻekiʻe.Loaʻa ka metabolism o ka fructose i loko o ke ake a me ke kiʻekiʻe o ka fructose flux e alakaʻi i ka hoʻonui ʻana o ka triglyceride hepatic (hepatic steatosis).ʻO kēia ka hopena i ka glucose a me ka lipid metabolism a hoʻonui i ka hōʻike cytokine proinflammatory.Maʻaneʻi, hōʻike mākou ua hoʻololi ka fructose i ka hōʻike hoʻoulu ʻia o ka glucose o ka acetyl CoA carboxylase (ACC), pSer hormone sensitive lipase (pSerHSL) a me adipose triglyceride lipase (ATGL) i loko o ka hepatic HepG2 a i ʻole nā ​​moʻomeheu cell hepatic mua in vitro.Hoʻopili ʻia kēia me ka hoʻonui ʻana i ka de novo triglyceride synthesis in vitro a me ka hepatic steatosis in vivo i ka fructose- versus glucose-fed a me nā ʻiole hānai maʻamau.Hāʻawi kēia mau haʻawina i ka ʻike hou i nā hana e pili ana i ka fructose-mediated hepatic hypertriglyceridemia a ʻike i ka fructose-uptake ma ke ʻano he pahuhopu therapeutic hou no nā maʻi pili lipid.